PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse | Zendy

Anna C. Calkin | Zendy; Sara Giunti | Zendy; Karin JandeleitDahm | Zendy; Terri J. Allen | Zendy; Mark E. Cooper | Zendy; Merlin C. Thomas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse

Author(s) -

Anna C. Calkin,

Sara Giunti,

Karin JandeleitDahm,

Terri J. Allen,

Mark E. Cooper,

Merlin C. Thomas

Publication year - 2006

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfl212

Subject(s) - rosiglitazone , medicine , endocrinology , albuminuria , kidney disease , renal function , glomerulosclerosis , streptozotocin , diabetic nephropathy , diabetes mellitus , kidney , gemfibrozil , insulin resistance , proteinuria , cholesterol

Peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists are widely used in diabetes. In addition to their effects on lipid and glucose homeostasis, these agents have been postulated to have independent renoprotective actions. In the current study, we assess the efficacy of the PPAR-alpha agonist, gemfibrozil, the PPAR-gamma agonist rosiglitazone and the non-thiazolidinedione PPAR-alpha/gamma coagonist, compound 3q, on kidney structure and function in streptozotocin-treated apolipoprotein E knockout mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research